Abstract
Objectives Small airways disease (SAD) is a major cause of airflow obstruction in COPD patients, and has been identified as a precursor to emphysema. Although the amount of SAD in the lungs can be quantified using our Parametric Response Mapping (PRM) approach, the full breadth of this readout as a measure of emphysema and COPD progression has yet to be explored. We evaluated topological features of PRM-derived normal parenchyma and SAD as surrogates of emphysema and predictors of spirometric decline.
Materials and Methods PRM metrics of normal lung (PRMNorm) and functional SAD (PRMfSAD) were generated from CT scans collected as part of the COPDGene study (n=8956). Volume density (V) and Euler-Poincaré Characteristic (χ) image maps, measures of the extent and coalescence of pocket formations (i.e., topologies), respectively, were determined for both PRMNorm and PRMfSAD. Association with COPD severity, emphysema, and spirometric measures were assessed via multivariable regression models. Readouts were evaluated as inputs for predicting FEV1 decline using a machine learning model.
Results Multivariable cross-sectional analysis of COPD subjects showed that V and χ measures for PRMfSAD and PRMNorm were independently associated with the amount of emphysema. Readouts χfSAD (β of 0.106, p<0.001) and VfSAD (β of 0.065, p=0.004) were also independently associated with FEV1% predicted. The machine learning model using PRM topologies as inputs predicted FEV1 decline over five years with an AUC of 0.69.
Conclusions We demonstrated that V and χ of fSAD and Norm have independent value when associated with lung function and emphysema. In addition, we demonstrated that these readouts are predictive of spirometric decline when used as inputs in a ML model. Our topological PRM approach using PRMfSAD and PRMNorm may show promise as an early indicator of emphysema onset and COPD progression.
Competing Interest Statement
Wassim W. Labaki reports personal fees from Continuing Education Alliance. Benjamin A. Hoff and Craig J. Galban are co-inventors and patent holders of tPRM, which the University of Michigan has licensed to Imbio, LLC. Craig J. Galban is co-inventor and patent holder of PRM, which the University of Michigan has licensed to Imbio, LLC. Benjamin A. Hoff and Craig J. Galban have financial interest in Imbio, LLC. Charles R. Hatt is employed by Imbio, LLC. David A. Lynch reports funds paid to the institution from NIH and personal payments from Boehringer Ingelheim. MeiLan K. Han reports personal fees from GlaxoSmithKline, AstraZeneca, Boehringer Ingelheim, Cipla, Chiesi, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Amgen, UpToDate, Altesa Biopharma, Medscape, NACE, MDBriefcase and Integrity. She has received either in kind research support or funds paid to the institution from the NIH, Novartis, Sunovion, Nuvaira, Sanofi, AstraZeneca, Boehringer Ingelheim, Gala Therapeutics, Biodesix, the COPD Foundation and the American Lung Association. She has participated in Data Safety Monitoring Boards for Novartis and Medtronic with funds paid to the institution. She has received stock options from Meissa Vaccines and Altesa Biopharma. For the remaining authors none were declared.
Funding Statement
This work was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health Grants R01 HL139690 (to Craig J. Galban), R01 HL150023 (to MeiLan K. Han, Craig J. Galban, and Charles R. Hatt) and T32 HL 007749 (to Jennifer M. Wang) and by the National Heart, Lung, and Blood Institute of the National Institutes of Health Grants U01 HL089897 and U01 HL089856, and NIH contract 75N92023D00011, which support the COPDGene study. The COPDGene study (NCT00608764) is also supported by the COPD Foundation through contributions made to an Industry Advisory Committee that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer and Sunovion.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Our study was a secondary analysis of data from COPDGene (ClinicalTrials.gov: NCT00608764). The institutional review boards of all 21 centers participating in the COPDGene study gave ethical approval for the work of that study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# co-last author
All supplemental material has been incorporated into the main text. This change provides a more accessible and comprehensive picture of our dictionary learning model; specifically, figures 6 and 7 are discussed in sequence to demonstrate how the model can identify COPD patients as fast or slow progressors. We have also added an author, Dr. Ravi Pal.
Data Availability
The datasets presented in this study are not readily available because they are part of an NIH sponsored clinical trial and require a data use agreement to be signed. For access to COPDGene data visit https://www.copdgene.org/phase-1-study-documents.htm for instructions.
